Journal
SUPPORTIVE CARE IN CANCER
Volume 28, Issue 12, Pages 6119-6128Publisher
SPRINGER
DOI: 10.1007/s00520-020-05706-4
Keywords
Bullous dermatoses; Corticosteroids; Cutaneous IrAEs; Inflammatory dermatitis; Pruritus; Skin rash; Vitiligo
Funding
- NIH/NIAMS [U01AR077511]
- NIH/NCI [P30 CA008748]
- Cancer Association of South Africa (CANSA)
- National Research Foundation (NRF) of South Africa
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available